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Background: Isolated case reports of gastric ulcers af-
ter alendronate sodium use raised concern about the gas-
troduodenal safety of daily alendronate. This study was
conducted to estimate the excess risk of hospitaliza-
tions for gastric or duodenal perforations, ulcers, and
bleeding associated with alendronate use.
Participants and Methods: Study subjects were 6432
men and women, 35 years or older. The subjects were
members of 8 health maintenance organizations who were
dispensed alendronate from October 1995 through Sep-
tember 1997. There was also a group of 33176 age-, sex-,
and health maintenance organization–matched unex-
posed persons. Because of concerns that osteoporosis
might confound the association between alendronate use
and perforation, ulcer, or bleeding, a second compari-
son group of 9776 women, 60 years or older, who had
osteoporotic fractures was assembled. Hospitalizations
for gastroduodenal events were identified by discharge
diagnosis codes in automated claims records, and con-
firmed by manual record review.
Results: Based on the 14 confirmed events in the alen-
dronate group and 35 in the unexposed group, the crude
incidence rate ratio of gastroduodenal perforation, ulcer,
or bleeding for the alendronate cohort was 3.0. The inci-
dence rate ratio was 1.8 (95% confidence interval, 0.8-
3.9) after control for prior hospitalizations, comorbidity,
and recent exposure to prescription nonsteroidal anti-
inflammatory drugs and oral corticosteroids. The crude in-
cidence ratio rate for the age, sex, and health maintenance
organizations–restricted cohort of alendronate users rela-
tive to the fracture cohort was 1.1 and the adjusted inci-
dence rate ratio was 1.1 (95% confidence interval, 0.6-2.2).
Conclusions: Osteoporosis and related factors appear
to play an important role in the relationship between alen-
dronate use and confirmed gastroduodenal perforation,
ulcer, or bleeding; a substantial fraction of the increased
risk we observed for alendronate users in the unad-
justed analysis was the result of confounding.
Arch Intern Med. 2002;162:936-942
T EN MILLION to 20 millionpostmenopausal women inthe United States have os-teoporosis. The enormousmedical, social, and eco-
nomicconsequencesaredueprimarilytoos-
teoporotic fractures; in 1995 they were re-
sponsibleforatleast400000hospitalizations,
2.5millionphysicianvisits, andmedicalex-
penditures of nearly $14 billion.1,2 Several
clinical trialshavedemonstratedtheefficacy
of alendronate sodium to treat osteoporo-
sisandpreventosteoporotic fractures.3-8 Al-
thoughesophageal irritationwasrecognized
as a potential side effect of alendronate, re-
ports to the Food and Drug Administration
in 1996 and 1997 raised concern that alen-
dronatemayhavepreviouslyunappreciated
potential forgastricandduodenal injury,es-
pecially among the elderly.9-11
This observational study was de-
signed to compare the incidence of hos-
pitalizations for gastric or duodenal per-
forations, ulcers, and bleeding among users
of alendronate with that among a ran-
domly selected, unexposed group. How-
ever, osteoporosis (the condition for which
alendronate is indicated) is associated with
excess nontrauma mortality12-14 and was
therefore a potential confounder in the as-
sociation between alendronate use and gas-
trointestinal injury. Although the preva-
lence of osteoporosis among the study
population could not be directly mea-
sured, we sought to approximate the mag-
nitude of this potential confounding effect
by comparing the rates of gastroduode-
nal perforations, ulcers, and bleeding in
a cohort of older women who had non-
pathologic fractures with age-matched
women exposed to alendronate.
RESULTS
STUDY COHORTS
A total of 6549 eligible men and women
35 years and older had 1 or more dispens-
ORIGINAL INVESTIGATION
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ings of alendronate between October 1, 1995, and Sep-
tember 30, 1997. Analysis was restricted to the 6432 per-
sons who were dispensed the 10-mg tablet exclusively.
Nearly 60% of the alendronate users were 65 years or
older, 3% were younger than 45 years, and 92% were
women (Table 1). The median number of 10-mg tab-
lets dispensed per person during the study period was
180; the median number of dispensings was 3. The me-
dian number of days from October 1, 1995, to the first
alendronate dispensing was 362, ranging from 16 to 730.
When comparing the alendronate users with the
33176 unexposed subjects, the median chronic disease
score for persons exposed to alendronate was 39% greater
than the unexposed group (Table 1). In 25 of 29 drug
categories used to compute the chronic disease score, alen-
dronate users were significantly more likely to have 1 or
more dispensings during the year before the first dis-
pensing of alendronate (or the random start date for the
unexposed group). Differences were most marked for per-
sons being treated for rheumatoid arthritis, asthma, and
gastric acid disorder. Persons dispensed alendronate were
73% more likely to have been hospitalized at least once
for any reason during the prior year than their unex-
posed counterparts.
There were 9776 women, 60 years or older, in the
fracture group and 3863 women in the corresponding sub-
set of age-sex-HMO–restricted alendronate users. These
2 groups had similar median chronic disease scores and
proportions of subjects who had at least 1 nonfracture
hospitalization during the previous year (Table 1).
INCIDENCE OF GASTRODUODENAL
PERFORATIONS, ULCERS, AND BLEEDING
From the HMO databases, 1376 hospitalizations with 1 or
more diagnoses of interest were identified from the 3 study
cohorts. The hospitalizations were approximately uni-
formly distributed during the study period. Hospital re-
cords were reviewed for 1041 (76%) of the 1376 potential
perforations, ulcers, or bleeding episodes; study person-
nel were denied access to most of those that were not re-
viewed. The proportion of charts unavailable for review was
PARTICIPANTS AND METHODS
STUDY POPULATION
This was a retrospective cohort study of health plan mem-
bers of 8 health maintenance organizations (HMOs) in geo-
graphically diverse locations. The institutional review board
of each HMO approved the study protocol. Membership,
demographic, drug dispensing, and hospital discharge in-
formation were obtained from automated databases at each
HMO. Eligible subjects were continuously enrolled in the
HMO for at least 1 year after October 1, 1994 (1 year be-
fore the initial marketing of alendronate), had prescrip-
tion drug coverage during the entire observation period,
and had hospital records generally accessible to study per-
sonnel. Three study cohorts (alendronate, unexposed, and
fracture) were identified.
The exposed cohort consisted of persons who were dis-
pensed 10-mg tablets of alendronate at least once from Oc-
tober 1995 through September 1997 and were 35 years or
older at the time of the first alendronate dispensing. Person-
time at risk for an individual started on the date alendro-
nate was dispensed and extended for a number of days equal
to the number of tablets dispensed, according to the rec-
ommended dose of 1 10-mg tablet per day. When dispens-
ings overlapped, the number of tablets dispensed in all such
dispensings was summed and time at risk was computed
from the first dispensing date. Only the first 15 days of a
gap in dispensing were considered alendronate-exposed
time. Person-time at risk ended on whichever of the fol-
lowing occurred first: September 30, 1997; first hospital-
ization for confirmed esophageal, gastric or duodenal per-
forations, ulcers, or bleeding; disenrollment; or the date that
the last dispensed alendronate pills were supposed to be
taken, plus 15 days. Since the 40- and 5-mg tablets were
infrequently dispensed (52 and 65 persons, respectively),
individuals who were given these dosages were not in-
cluded in the study.
The unexposed cohort was frequency matched to the
alendronate cohort with respect to age and sex at a ratio of
5:1 within each HMO. These individuals were not given alen-
dronate and person-time at risk for each was counted from
a randomly chosen referent date after October 1, 1995, to
whichever the following occurred first: September 30, 1997;
first hospitalization for confirmed esophageal, gastric, or duo-
denal perforations, ulcers, or bleeding; or disenrollment.
The fracture cohort was composed of women older than
60 years as of October 1, 1994, judged to have a high preva-
lence of osteoporosis. They were from 7 of the 8 participat-
ing HMOs, and had at least 1 diagnosis code between Oc-
tober 1994 and September 1997 for fracture of the hip,
humerus, distal tibia, vertebrae, or wrist in ambulatory or
hospital records. Women who had at least 1 diagnosis code
that represented bone cancer, breast cancer, colon cancer,
lung cancer, cancer metastasis, multiple myeloma, concur-
rent major trauma, or pathologic fracture were excluded. As
part of a secondary analysis, the fracture cohort was further
subdivided into a hip fracture group and a nonhip fracture
group. Women who had multiple fractures, one being a hip
fracture, were classified as having hip fracture. Diagnosis codes
for hip fracture have been reported to have high predictive
value positive rates.15 We reviewed medical records of a ran-
dom sample of 404 women who fulfilled the selection cri-
teria for nonhip fractures to evaluate the accuracy of the frac-
ture identification algorithm. We calculated the proportion
of true positives for each nonhip anatomic site at each HMO
and excluded cases of fracture sites from HMOs that had a
true-positive rate of less than 60%. Among the remaining frac-
ture groups reviewed, 314 (82%) of 383 women were con-
firmed to have a nonpathologic fracture. Fracture-exposed
person-time started on October 1, 1995, and continued un-
til the earliest of September 30, 1997; disenrollment; first dis-
pensing of alendronate; or first hospitalization for con-
firmed esophageal, gastric, or duodenal perforations, ulcers,
or bleeding.
Continued on next page
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similar between alendronate users (28%) and unexposed
individuals (30%), but lower for the fracture cohort (18%).
Alendronate Users vs Unexposed Cohort
Among the alendronate and unexposed cohorts, 167 (28%)
cases of upper gastrointestinal perforation, ulcer, or bleed-
ing were confirmed by record review; 155 were gastroduo-
denal and 12 were esophageal. Of the 155 persons with gas-
troduodenal perforation, ulcer, or bleeding, 49 (32%) had
their event during at-risk person-time; 14 were alendro-
nate users and 35 were from the unexposed group. No per-
son had more than 1 confirmed event. For most cases among
the alendronate users, the perforation, ulcer, or bleeding
event occurred at a time relatively distant from their ini-
tial alendronate dispensing (median, 198 days). The inci-
dence rates of gastroduodenal perforation, ulcer, or bleed-
ing at various durations of alendronate therapy were not
significantly different (P=.59; Table 2).
The crude incidence rate of gastroduodenal perfora-
tion, ulcer, or bleeding for the alendronate cohort (3.4 per
1000 person-years) was 3 times (95% CI, 1.6-5.5) greater
than the crude rate for the unexposed group (1.1 per 1000
person-years). The IRR was 1.8 (95% CI, 0.8-3.9) after ad-
justment for age, sex, chronic disease score, recent expo-
sure to prescription NSAIDs and oral corticosteroids, and
the number of hospitalizations in the year before the first
dispensing of alendronate (or the referent date for the un-
exposed group; Table 3). When terms for the interac-
tion of alendronate exposure with prescription NSAIDs and
oral corticosteroids were included in the full model, only
the term for corticosteroids significantly improved the fit
of the model (P.03). Stratified regression analysis showed
an adjusted IRR of 2.8 (95% CI, 1.4-5.8) for those with-
out recent use of oral corticosteroids and an adjusted IRR
of 2.6 (95% CI, 1.1-6.3) for those with no recent NSAID
use. The IRR was less than 1, with wide CIs, for those with
recent use of drugs from either category, but there were
few patients in these strata and the estimates were un-
stable (data not shown).
The event rate among alendronate users during time
not exposed to alendronate was not significantly differ-
ASCERTAINMENT OF OUTCOMES
Persons with upper gastrointestinal events of interest were
identified in each HMO by a 3-step procedure: (1) com-
puterized search of claims files; (2) abstraction of hospital
records; and (3) confirmation of perforations, ulcers, or
bleeding. Hospital claims files were searched with Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modi-
fication codes from October 1995 through September 1997
for the discharge diagnoses of gastric ulcer (531.xx), duo-
denal ulcer (532.xx), peptic ulcer (533.xx), gastrojejunal
ulcer (534.xx), gastrointestinal hemorrhage (578.xx), or
esophageal ulcer (530.2). Full-text hospital records from
hospitalizations with any one of these codes were re-
viewed to abstract additional information to confirm or re-
ject the diagnosis and to determine the time of onset of signs
and symptoms (before or after admission to the hospital).
Three investigators (J.G.D., K.A.C., and R.P.) who were
blinded to alendronate exposure status, reviewed the ano-
nymized abstraction forms. The second reviews were con-
ducted for all individuals except those for whom the pri-
mary review clearly indicated that there was no perforation,
ulcer, or bleeding. Final arbitration of the small number
of indeterminate records that remained was performed in
a blinded manner by a gastroenterologist (T.R.L.).
Persons were classified as cases if they were hospital-
ized for esophageal, gastric, or duodenal ulcer as con-
firmed by surgery, endoscopy, radiology, or autopsy. In ad-
dition, cases included persons with upper gastrointestinal
hemorrhage determined by surgery, endoscopy, radiol-
ogy, or autopsy to originate from esophageal, gastric, or duo-
denal ulcer; hemorrhagic gastritis; or duodenitis. Ex-
cluded from both the case and comparison groups were
persons with esophageal, gastric, or duodenal events with
onset during hospitalization or other specified pathologi-
cal conditions (eg, neoplasm). Cases of duodenal and py-
loric ulcer were classified as “duodenal ulcer.” Cases of
gastric, gastrojejunal, and gastric or duodenal ulcer occur-
ring simultaneously were classified as “gastric ulcer.”16
Persons with nonprimary esophageal ulcers concurrent with
gastric or duodenal ulcers were also classified by either gas-
tric or duodenal ulcer as noted above.
ADJUSTMENT FOR COMORBIDITY
Comorbidity was assessed through the chronic disease score,
which is based on age, sex, and dispensings of prescrip-
tion drugs used to treat specific chronic diseases during the
previous 12 months.17,18 The scores are directly related to
and predictive of utilization of health care resources; higher
scores reflect higher health care costs.17-19
DATA ANALYSIS
We used the method of Breslow to estimate the incidence rate
ratios (IRRs) and 95% confidence intervals (CIs).20 The pro-
tocol-defined primary analysis was to compare the inci-
dence of gastric or duodenal perforations, ulcers, and bleed-
ing among the alendronate cohort, the unexposed cohort, and
the fracture cohort. Secondary analyses included the evalu-
ation of event rates among the hip and nonhip fracture groups
and comparisons with the age-sex-HMO–restricted alendro-
nate cohort. The impact of potential effect modification and
confounding by oral corticosteroids and prescription non-
steroidal anti-inflammatory drugs (NSAIDs) was assessed by
stratification and regression modeling. Individuals with a con-
firmed event were classified as exposed to prescription NSAIDs
if they were dispensed a prescription NSAID during the 45
days of eligible person-time before onset of the event. Per-
sons without an event were classified as exposed if a pre-
scription NSAID was dispensed during the 45 days preced-
ing a randomly chosen date during eligible person-time. A
similar strategy was used to classify oral corticosteroid ex-
posure. We used Poisson regression to obtain the hazard rate
estimates under a censored exponential event-time model.21
Confidence intervals were formed with model-robust SEs that
are consistent regardless of the adequacy of the exponential
model for the process under consideration.22
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ent from the rate during alendronate-exposed time (2.4
vs 3.4 per 1000 person-years; P=.25), but it was greater
than the rate among the unexposed cohort (1.1 per 1000
person-years; P.001).
Alendronate Users vs Fracture Cohort
Ten of the 14 gastroduodenal perforations, ulcers, or bleed-
ing events among alendronate users described above were
among the 3863 women of the age-sex-HMO–restricted co-
hort. There were 58 confirmed gastroduodenal perfora-
tions, ulcers, or bleeding events in the fracture cohort. Crude
IRR for age-sex-HMO–restricted alendronate users rela-
tive to the fracture cohort was 1.1 (95% CI, 0.6-2.3). The
IRR was unchanged after controlling for age, chronic dis-
ease score, recent exposure to prescription NSAIDs and oral
corticosteroids, and the number of nonfracture related hos-
pitalizations during the previous year (IRR, 1.1; 95% CI,
0.6-2.2; Table 3). Interaction terms between alendronate
use and NSAID exposure and alendronate use and oral cor-
ticosteroid exposure were not significant.
When the fracture cohort was further stratified into
the hip fracture group and the nonhip fracture group, the
adjusted IRR of gastroduodenal perforations, ulcers, and
bleeding for alendronate users relative to the hip fracture
group (IRR, 0.6; 95% CI, 0.3-1.2) was substantially differ-
Table 1. Baseline Characteristics of the Study Cohorts
Characteristic
Alendronate (Full)
(n = 6432)
Unexposed
(n = 33 176)
Alendronate (Women Aged 60 y)
(n = 3865)
Fracture
(n = 9776)
Age, median (range), y 67 (35-97) 67 (35-105) 72 (60-97) 75 (60-104)
Women, % 92 91 100 100
Chronic disease score, median 3829 2756 5573 5495
Hospitalized during year prior to index date, %* 19 11 19 19
Chronic disease score categories†
Rheumatoid arthritis 26.3 8.9 30.1 16.2
Gastric acid disorder 24.2 16.0 37.0 29.2
Malignancies 9.8 2.9 11.9 3.6
Asthma/respiratory illness 28.6 19.5 41.7 39.2
*Index date was date of first alendronate sodium dispensing for the alendronate cohort, the randomly selected reference date for the comparison cohort, and
October 1, 1995, for the fracture cohort. Only nonfracture hospitalizations were counted for the fracture group.
†Percentage of persons with 1 or more dispensings of drugs used to treat selected chronic diseases during the year before the index date. The chronic disease
score categories shown are the most directly relevant to upper gastrointestinal tract disease.
Table 2. Rate of Confirmed Gastroduodenal Perforation, Ulcers, and Bleeding by Duration of Alendronate Therapy
Duration of Alendronate Therapy, d
Total1-30 31-90 91
No. of confirmed events* 2 1 11 14
Person-time at risk, y 515 868 2755 4138
Incidence rate (95% CI)† 3.9 (0.5-14.0) 1.1 (0.0-6.4) 4.0 (2.0-7.1) 3.4 (1.8-5.7)
*Restricted to gastroduodenal events that occurred during alendronate sodium−exposed time.
†Unadjusted incidence rate (per 1000 years). 2 Test for trend = 0.29, P = .59. CI indicates confidence interval.
Table 3. Adjusted Incidence Rate Ratios for Gastroduodenal Perforation, Ulcers, and Bleeding Derived
From Poisson Regression Models*
Incidence Rate Ratio (95% CI)
Alendronate Users (n = 6432)
vs Unexposed Cohort
(n = 33 176)
Age-Sex-HMO−Restricted Alendronate Users
(n = 3865) vs Fracture Cohort
(n = 9776)
Alendronate sodium 1.81 (0.83-3.94) 1.11 (0.56-2.19)
Female 0.39 (0.19-0.81) Not applicable
Hospitalizations during previous year† 1.11 (0.88-1.40) 1.14 (0.88-1.47)
Chronic disease score (per 1000) 1.06 (1.02-1.11) 1.06 (1.04-1.08)
Corticosteroid exposure‡ 4.50 (1.92-10.55) 1.33 (0.52-3.39)
Prescription NSAID exposure‡ 3.28 (1.70-6.33) 3.33 (1.94-5.72)
*CI indicates confidence interval; HMO, health maintenance organization; and NSAID, nonsteroidal anti-inflammatory drug. Age was controlled for as indicator
variables in 10-year age groups.
†Only nonfracture hospitalizations were counted for the age-sex-HMO−restricted alendronate users and the fracture cohort.
‡Exposure to corticosteroids and prescription NSAIDs was defined as a dispensing within 45 days before the date for a confirmed gastroduodenal event and
within 45 days before a random date for subjects without confirmed gastroduodenal event.
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ent from that for alendronate users relative to the nonhip
fracture group (IRR, 1.6; 95% CI, 0.7-3.3). Women with
hip fractures represented only 29% of the fracture cohort,
but they generated more than 50% of the confirmed per-
forations, ulcers, or bleeding events in the fracture group.
ESOPHAGEAL PERFORATIONS, ULCERS,
AND BLEEDING
There were 20 confirmed esophageal perforations, ul-
cers, or bleeding events without gastric or duodenal ul-
cers; 1 occurred during exposure to alendronate, 5 after
the referent date in the unexposed group, 7 among the
fracture group, and the rest occurred during ineligible
person-time. No further analysis was performed for esoph-
ageal lesions because of the small number of events.
COMMENT
We conducted a retrospective cohort study of nearly 50000
persons to investigate a possible association between alen-
dronate and confirmed gastroduodenal perforation, ulcer,
or bleeding resulting in hospitalization. Because of the po-
tential for confounding by indication (ie, osteoporosis), es-
timates of the effect of alendronate were computed with 2
separate comparison groups. Although neither estimate was
statistically significant, theywere substantiallydifferent,with
a smaller (nonsignificant) excess risk when the fracture co-
hort was used as the comparison group. Not surprisingly,
the fracture group was heterogeneous with respect to the
risk of these gastroduodenal events; the adjusted rate ra-
tios were markedly different when the alendronate group
was separately compared with those with hip fracture and
those with nonhip fracture.
We considered osteoporosis a potential confounder
of thealendronateandgastroduodenalperforations,ulcers,
andbleedingrelationshipbecauseof the increasedmorbid-
ity and mortality in persons with osteoporosis.12-14 The ex-
cessmorbiditycanbeattributed tounderlyingdiseasesand
osteoporotic fractures, especially fractures of the hip and
vertebrae23; the consequences of nonhip fractures such as
wrist and humerus are substantially less.12,24 The relation-
ship between alendronate use and upper gastrointestinal
adverseevents is furthercomplicatedbytheincreasedpreva-
lenceofgastrointestinal symptoms in theelderly.25 Persons
dispensedalendronate inthepresentstudyappearedtohave
greatermorbiditythantheunexposedgroup;theyweremore
likely tohavebeenhospitalized in thepreceding12months
andtheirchronicdiseasescoreswerehigher.Moreover, they
weresubstantiallymore likely tohavebeendispenseddrugs
that either predispose to peptic ulcers (eg, prescription
NSAIDs and oral corticosteroids) or are used to treat con-
ditions that may progress to peptic ulcers (eg, histamine2
antagonists). Taken together, it appears that persons using
alendronatemayhavehadagreaterunderlyingriskofagas-
troduodenal adverseevent thanpersonsnotusingalendro-
nate, and this may have accounted for the decrease in ob-
served risk after control for potential confounders. Alen-
dronate recipients’ nearly equal rate of perforation, ulcer,
or bleeding during periods when they were not exposed to
alendronateandperiodswhentheywereexposed lends fur-
ther support to this possibility.
The ideal group with which to compare alendronate-
exposed persons would have osteoporosis at the same rate
and intensity but without exposure to alendronate. How-
ever, coded diagnoses of osteoporosis were not uniformly
available in the automated databases of the HMOs partici-
pating in this study, and the misclassification inherent in
the diagnosis of osteoporosis would result in a biased sample
of persons with osteoporosis. We postulated that a com-
parison group consisting of older women (men were ex-
cluded from the fracture cohort) with osteoporotic frac-
tures would be subject to less misclassification, and although
not representative of all persons with osteoporosis, they
would be more likely to have osteoporosis than a ran-
domly selected comparison group. In fact, the general risk
profile of the fracture cohort closely approximated the pro-
file of the corresponding alendronate cohort; the 2 groups
had comparable chronic disease scores and nonfracture hos-
pitalization rates in the preceding 12 months. It should be
noted, however, that the fracture cohort was not homoge-
neous with respect to the risk of gastroduodenal adverse
events. Compared with women with nonhip fractures, those
with hip fractures accounted for a disproportionate num-
ber of gastroduodenal perforations, ulcers, and bleeding.
We do not know whether this difference is a reflection of
more severe osteoporosis in women with hip fracture or
whether such women have a greater prevalence of other
unmeasured risk factors for these adverse events.
Although gastric and duodenal adverse events were
reported in some of the alendronate clinical trials, their
occurrence was no greater in those treated with alendro-
nate than in the placebo groups.4,8,26 Nor were there sig-
nificant differences between the treatment groups in the
overall incidence of adverse events leading to discontinu-
ation of study medication. Bauer et al26 combined the 2
study arms of the Fracture Intervention Trial and deter-
mined that the rate of gastroduodenal adverse events among
over 6400 women with osteoporosis was nearly equal in
the alendronate and placebo treatment groups. Although
there are important methodological differences between
the Bauer et al study and ours that limit comparisons (eg,
their cases included hospitalized as well as nonhospital-
ized cases), the risks of gastroduodenal adverse events ap-
pear to be similar. For example, the event rates among alen-
dronate-exposed women (55-64, 65-74, and 75-84 years
old) in the present study were 1.1, 4.9, and 4.4 per 1000
person-years, respectively. These rates approximate the age-
specific rates reported by Bauer et al.26
Nitrogen-containing bisphosphonates, including
alendronate, have the potential to cause mucosal irrita-
tion. Studies in laboratory animals have demonstrated
that alendronate is a topical irritant capable of inflicting
erosions and enhancing indomethacin-induced ulcer-
ation of the esophagus and stomach.27,28 In addition, a
number of case reports have described esophagitis and
esophageal ulcers subsequent to ingestion of alendro-
nate.9,10,29-31 Less common and conflicting have been re-
ports of alendronate-associated gastroduodenal ul-
cers.11,32 A retrospective cohort study determined that
older women taking alendronate were more likely to
experience acid-related disorders of the upper gastroin-
testinal tract than a group of nonalendronate users not
selected for osteoporosis.33
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Our study had approximately 65% power to detect
a 2-fold increase in risk of gastroduodenal perforations,
ulcers, and bleeding for the comparison between the alen-
dronate and the unexposed cohorts. Additional limita-
tions pertain to the type and level of detail in automated
medical records. We had no data on risk factors such as
alcohol use, smoking, Helicobacter pylori infection, or fam-
ily history of osteoporosis and peptic ulcer disease. Per-
haps more important, we had no information on over-
the-counter medications, such as nonprescription NSAIDs,
that are known to promote gastrointestinal ulcers.16 If the
alendronate-exposed individuals in our study, who were
significantly more likely to have filled prescriptions for
NSAIDs, were also more likely to use over-the-counter
NSAIDs than those not exposed to alendronate, then we
may have overestimated the relative risk of gastroduo-
denal perforations, ulcers, and bleeding. We probably
overestimated exposure since we assumed that all dis-
pensed alendronate tablets were taken, and we have no
method to evaluate compliance using automated data. This
type of misclassification of exposure would bias the effect
measure toward an apparent null effect. Although the frac-
ture types that defined the fracture cohort were known
to be associated with osteoporosis,1,34 it is likely that some
individuals in the fracture cohort did not have osteopo-
rosis. Although we were not able to review all potential
cases of outcomes of interest, the very specific confir-
mation criteria that we used for gastroduodenal perfo-
rations, ulcers, and bleeding make it unlikely that this
would have biased the estimate of the relative risk.35
The choice of an appropriate comparison group is
crucial to the understanding of the association between
alendronate and gastroduodenal perforations, ulcers, and
bleeding. To the extent that osteoporosis is a risk factor
for these adverse events, the observed relative risk de-
rived by comparing alendronate users with a group with
less morbidity and lower prevalence of osteoporosis (ran-
domly selected, not exposed to alendronate) is probably
an overestimate. To the extent that nonpathologic frac-
tures are good markers for osteoporosis in older women,
the measure of effect derived by comparing alendronate
users with those with selected fractures may be more ac-
curate. It is also possible that the fracture cohort, nearly
30% of which had a hip fracture, had a greater level of
morbidity, and the rate ratio would be biased toward
the null. These results underscore the need to consider
the severity of osteoporosis and comorbidity to prop-
erly interpret the risk of gastroduodenal adverse events
in patients being treated for osteoporosis.
Although the crude analysis demonstrated a 3-fold
increase in the risk of gastroduodenal perforations, ul-
cers, and bleeding among patients dispensed alendronate,
a substantial fraction of this association was attributable
to comorbid conditions and other factors. The role of os-
teoporosis as inferred from fractures is both important and
complex; countervailing risks of gastroduodenal adverse
events depended on the presence of hip fractures in the com-
parison group. A clearer understanding of the morbidity
associated with osteoporosis would more completely elu-
cidate the relationship between alendronate use and gas-
troduodenal perforations, ulcers, and bleeding.
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